石家庄格瑞药业有限公司
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
55
NMPA:55
Drug Approvals
Brimonidine Tartrate and Timolol Maleate Eye Drops
- Product Name
- 溴莫尼定噻吗洛尔滴眼液
- Approval Number
- 国药准字H20254074
- Approval Date
- May 13, 2025
NMPA
Olopatadine Hydrochloride Eye Drops
- Product Name
- 盐酸奥洛他定滴眼液
- Approval Number
- 国药准字H20254150
- Approval Date
- May 13, 2025
NMPA
Diquafosol Sodium Eye Drops
- Product Name
- 地夸磷索钠滴眼液
- Approval Number
- 国药准字H20253908
- Approval Date
- Apr 15, 2025
NMPA
Diquafosol Sodium Eye Drops
- Product Name
- 地夸磷索钠滴眼液
- Approval Number
- 国药准字H20253907
- Approval Date
- Apr 15, 2025
NMPA
Brimonidine Tartrate Eye Drops
- Product Name
- 酒石酸溴莫尼定滴眼液
- Approval Number
- 国药准字H20253730
- Approval Date
- Mar 25, 2025
NMPA
Olopatadine Hydrochloride Eye Drops
- Product Name
- 盐酸奥洛他定滴眼液
- Approval Number
- 国药准字H20249755
- Approval Date
- Dec 17, 2024
NMPA
Olopatadine Hydrochloride Eye Drops
- Product Name
- 盐酸奥洛他定滴眼液
- Approval Number
- 国药准字H20249754
- Approval Date
- Dec 17, 2024
NMPA
Naphazoline Hydrochloride Nasal Drops
- Product Name
- 盐酸萘甲唑啉滴鼻液
- Approval Number
- 国药准字H20247279
- Approval Date
- Nov 7, 2024
NMPA
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
No trials found
News
No news found